Roche’s Anderson to depart
Plus: Perreault retires as McKenzie becomes CEO at CSL, and updates from Wren and OptiNose
Bill Anderson will step down as CEO of Roche Pharmaceuticals on Dec. 31 to pursue opportunities outside of Roche (SIX:ROG; OTCQX:RHHBY). Thomas Schinecker, Roche’s incoming CEO and current CEO of Roche Diagnostics, will become interim CEO of the pharmaceutical division on Jan. 1, until a successor is announced. Anderson first joined Genentech Inc. in 2006 as SVP of immunology and ophthalmology business unit, before becoming CEO in 2019.
As previously announced, Schinecker will succeed Severin Schwan as Roche Group CEO on March 15, with the company’s board proposing that Schwan succeed Christoph Franz as chairman. The board is also proposing two new board members: Mark Schneider, CEO of Nestlé S.A. (SIX:NESN), and Akiko Iwasaki, professor of immunobiology and molecular, cellular and developmental biology at Yale University...